US 12,089,971 B2
Bioprosthetic heart valves having adaptive seals to minimize perivalvular leakage
Qinggang Zeng, Mission Viejo, CA (US); Chacphet Limsakoune, Corona, CA (US); Diana E. Ko, Irvine, CA (US); and Christina M. Aguila, Foothill Ranch, CA (US)
Assigned to EDWARDS LIFESCIENCES CORPORATION, Irvine, CA (US)
Filed by Edwards Lifesciences Corporation, Irvine, CA (US)
Filed on Jul. 24, 2020, as Appl. No. 16/938,899.
Application 16/938,899 is a continuation of application No. 15/792,441, filed on Oct. 24, 2017, granted, now 10,722,316.
Application 15/792,441 is a continuation of application No. 14/533,922, filed on Nov. 5, 2014, abandoned.
Claims priority of provisional application 61/900,827, filed on Nov. 6, 2013.
Prior Publication US 2020/0352670 A1, Nov. 12, 2020
Int. Cl. A61F 2/24 (2006.01); A61B 50/30 (2016.01); A61F 2/00 (2006.01); A61B 50/00 (2016.01); A61B 50/33 (2016.01)
CPC A61B 50/30 (2016.02) [A61F 2/0095 (2013.01); A61F 2/2412 (2013.01); A61F 2/2415 (2013.01); A61B 2050/002 (2016.02); A61B 50/33 (2016.02); A61F 2/2418 (2013.01); A61F 2250/0069 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A bioprosthetic heart valve comprising:
a dry biological tissue leaflet structure comprising an inflow portion and an outflow portion;
a sewing ring defining the inflow portion of the dry biological tissue leaflet structure; and
an adaptive seal provided in connection with the sewing ring;
wherein the adaptive seal comprises an expandable material configured to expand after exposure to an initiating condition;
wherein the expandable material is a substantially dehydrated hydrogel that has been crosslinked with a biodegradable crosslinker; and
wherein the dry biological tissue leaflet structure, the sewing ring, and the adaptive seal are configured for storage in a sealed package that does not contain a liquid storage solution.